Pursuant to Regulation 24(A) of SEBI(LODR), Regulations, 2015, enclosed is the Annual Secretarial Compliance Report for the year ended on 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
ANG Lifesciences India Ltd has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2025, as required under Regulation 24A of SEBI (LODR) Regulations. The report, issued by Practicing Company Secretary Anil Singh Negi (M/s Anil Negi & Company), confirms that the company has broadly complied with applicable SEBI regulations, circulars, and secretarial standards during the review period. One specific non-compliance was flagged: a delay in submitting the Reconciliation of Share Capital Audit Report under Regulation 76 of SEBI (Depositories & Participants) Regulations, 2018 for the quarters ended June 2024 and September 2024, though the company has since regularised these filings. Additionally, the statutory auditor resigned on 14th August 2024 (within 45 days from the end of the June 2024 quarter) and issued the limited review report before resignation, in line with SEBI norms. No actions were taken against the company, its promoters, or directors by SEBI or stock exchanges during the year.
This is a routine annual compliance filing and not a material event for shareholders. The flagged delay in share capital audit reconciliation for two quarters is a minor procedural lapse that has already been corrected, with no penalty or ongoing regulatory action. The report does not signal any governance concerns that should materially affect the stock price or shareholder interests.